John Demaree

KPTI

CHIEF COMMERCIAL OFFICER · KARYOPHARM THERAPEUTICS INC. · CIK 0001744959

FILING MIX · LIFETIME100%/0%

BUYS

SELLS

TOTAL VALUE

$109.0K

COMPANIES

ACTIVE SINCE

Mar 2020

HOLDINGS NOW

43,177

AVG SELL PX

—

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

1 backtested trades · 8 horizons

Forward-return performance of every backtestable P/S trade by John Demaree, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	1	+100.00%	+9.03%	+2.91%	+6.12%	+6.12%	—
14d	1	+100.00%	+6.05%	-2.23%	+8.28%	+8.28%	—
30d	1	+100.00%	+3.13%	-5.04%	+8.17%	+8.17%	—
60d	1	+100.00%	+10.08%	-1.96%	+12.04%	+12.04%	—
90d	1	+100.00%	+5.77%	+4.92%	+0.84%	+0.84%	—
180d	1	+100.00%	+3.68%	+12.28%	-8.59%	-8.59%	—
1y	1	+0.00%	-64.42%	+30.31%	-94.73%	-94.73%	—
2y	1	+0.00%	-64.42%	+20.04%	-84.46%	-84.46%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

KPTI · 43,177 shares · as of Feb 25, 2021

Trading cadence · quarterly flow

BUY ● SELL ●

2020

2021

FLOW · 4 buys / 0 sellsCOVERAGE · 5 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	15,849	—	—	23,995	Feb 25, 2021	Mar 1, 2021 ↗
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	43,177	—	—	43,177	Feb 25, 2021	Mar 1, 2021 ↗
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASE Chief Commercial Officer	7,500	$14.54	$109.0K	7,500	Aug 26, 2020	Aug 27, 2020 ↗
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	151,200	—	—	151,200	Mar 16, 2020	Mar 17, 2020 ↗

Other insiders · KPTI

Loading peer insiders…

About this filer

CIK 0001744959

ROLE

Chief Commercial Officer

PRIMARY

KPTI

COMPANIES

ACTIVE SINCE

Mar 2020

MARKETPEEL · /INSIDER/0001744959DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

John Demaree

The morning brief, before the bell.